Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)

• Published in: Oncotarget 2018-04, Vol.9 (25), p.17554-17563
• Main Authors: Vecchiarelli, Silvia, Passiglia, Francesco, D'Incecco, Armida, Gallo, Marianna, De Luca, Antonella, Rossi, Elisa, D'Incà, Federica, Minuti, Gabriele, Landi, Lorenza, Bennati, Chiara, Spreafico, Michela, D'Arcangelo, Manolo, Mazza, Valentina, Normanno, Nicola, Cappuzzo, Federico
• Format: Article
• Language: English
• Subjects: Research Paper
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.24785

This study aimed at investigating feasibility of programmed death ligand-1 (PD-L1) testing in plasma samples of advanced NSCLC patients receiving first-line treatment, assessing whether circulating (c)PD-L1 levels were modified by the therapy and whether baseline cPD-L1 levels were associated with patients' clinical responses and survival outcome. Peripheral blood samples were collected from 16 healthy volunteers and 56 newly diagnosed NSCLC patients before and at 12th week during the course of first-line therapy. The level of PD-L1 was measured in plasma samples using the human (PD-L1/CD274) ELISA kit (CUSABIO, MD, USA). The Mann Whitney test or Fisher's test were used for comparisons. Survival analysis was performed using Kaplan Meyer method, providing median and -value. Baseline median cPD-L1 was 42.21 pg/ml (range 12.00-143.49) in NSCLC patients and 37.81 pg/ml (range 9.73-90.21) in healthy control cohort ( = 0.78). Median cPD-L1 increased in patients treated with first-line chemotherapy (63.20 pg/ml vs 39.34 pg/ml; = 0.002), with no changes in patients exposed to non-chemotherapy drugs (42.39 pg/ml vs 50.67 pg/ml; = 0.398). Time to progression and overall survival were 4.4 vs 6.9 months ( = 0.062) and 8.8 vs 9.3 months ( = 0.216) in cPD-L1 positive vs cPD-L1 negative patients. Baseline cPD-L1 levels increased with the ascending number of metastatic sites, even if the association was not statistically significant ( = 0.063). This study showed that cPD-L1 testing is feasible, with chemotherapy influencing PD-L1 plasma levels. The possibility of using such test for predicting or monitoring the effect of immunotherapy or combination of chemotherapy and immunotherapy warrant further investigations.